An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 87-97

  Bird, R Curtis ^a   DeInnocentes, Patricia ^a   Church Bird, Allison E ^a   Van Ginkel, Frederik W ^a   Lindquist, Joni ^a   Smith, Bruce F ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Autologous; Canine mammary cancer; Dendritic cells; Hybrid cell fusion; Vaccine

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; OLIGONUCLEOTIDE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNIZATION; CELL FUSION; CELL POPULATION; CELL STRAIN; CELL STRAIN CMT; CONTROLLED STUDY; DOG; HYBRID CELL; LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL FUSION; CELL LINE, TUMOR; CELL SEPARATION; CHIMERA; DENDRITIC CELLS; DOGS; FEMALE; FLOW CYTOMETRY; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, ANIMAL;

EID: 79953743156     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0921-2     Document Type: Article

References (39)

1. MacEwen EG, Withrow SJ (1996) Tumors of the mammary gland. In: Withrow SJ, MacEwen EG (eds) Small animal oncology. Saunders, Philadelphia, pp 356-372
2. Wolfe LG, Smith BB, Toivio-Kinnucan MA, Sartin EA, Kwapien RP, Henderson RA, Barnes S (1986) Biologic properties of cell lines derived from canine mammary carcinomas. J Natl Cancer Inst 77:783-791
3. Sartin EA, Barnes S, Toivio-Kinnucan M, Wright JC, Wolfe LG (1993) Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and sensitivity to tamoxifen and doxorubicin. Anticancer Res 13:229-236 (Pubitemid 23118226)
4. Schneider R, Dorn CR, Taylor DN (1969) Factors inXuencing mammary cancer development and post-surgical survival. J Natl Cancer Inst 43:1249-1261
5. Macewen EG (1990) Spontaneous tumors of dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis 9:125-136
6. Martin PM, Cotard M, Miolot JP, Andre JP, Raynaud JP (1984) Animal models for hormone-dependent human breast cancer: relationship between steroid receptor proWles in canine and feline mammary tumors and survival rate. Canc Chemother Pharmacol 12:13-17 (Pubitemid 14216732)
7. Ahern TE, Bird RC, Church Bird AE, Wolfe LG (1995) Overexpression of the oncogene c-erbB-2 in canine mammary carcinomas and tumor-derived cell lines. Am J Vet Res 57:693-696
8. DeInnocentes P, Li LX, Sanchez RL, Bird RC (2006) Expression and sequence of canine SIRT2 and p53 genes in canine mammary tumor cells: effects on down-stream targets Wip1 and p21/Cip1. Vet Comp Oncol 4:161-177
9. DeInnocentes P, Agarwal P, Bird RC (2009) Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer. J Cell Biochem 106:491-505
10. Migone F, Bird RC, DeInnocentes P, Lenz S, Smith B (2006) Alterations in CDK1 expression and localization following induction in a spontaneous canine mammary cancer model. J Cell Biochem 98:504-518 (Pubitemid 43739344)
11. Bird RC (2009) Defects in genes regulating the cell cycle in spontaneous canine models of cancer. In: Yoshida K (ed) Trends in cell cycle research. Research Sign Post, Kerala, pp 209-236
12. Timmerman JM, Levy R (1998) Melanoma vaccines: prim and proper presentation. Nat Med 4:269-270 (Pubitemid 28144077)
13. Nair SK (1998) Immunotherapy of cancer with dendritic cell-based vaccines. Gene Ther 5:1445-1446
14. Souberbielle BE, Westby M, Ganz S, Kayaga J, Mendes R, Morrow WJ, Dalgleish AG (1998) Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Ther 5:1447-1454
15. Steinman RM (1996) Dendritic cells and immune-based therapies. Exp Hematol 24:859-862
16. Schuler G, Steinman RM (1997) Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 86:1183-1187 (Pubitemid 27469012)
17. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97:2715-2718 (Pubitemid 30159237)
18. Stuhler G, Trefzer U, Walden P (1998) Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti-tumor cytotoxic T cells. Adv Exp Med Biol 451:277-282
19. Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P, Dalgleish AG (2000) Human tumor and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 1500:265-279 (Pubitemid 30123057)
20. Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T (2001) Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24:106-113 (Pubitemid 32183056)
21. Bird RC, DeInnocentes P, Lenz S, Thacker EE, Curiel DT, Smith BF (2008) An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. Vet Immunol Immunopathol 123:289-304
22. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault J-C, Villarroel M, Kufe D (2004) Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10:4699-4708 (Pubitemid 38955520)
23. Homma S, Sagawa Y, Ito M, Ohno T, Toda G (2006) Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol 144:41-47
24. Kircheis R, Kupcu Z, Wallner G, Rossler V, Schweighoffer T, Wagner E (2000) Interleukin-2 gene-modiWed allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice. Cancer Gene Ther 7:870-878 (Pubitemid 30437287)
25. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332 (Pubitemid 28144092)
26. Hadzantonis M, O'Neill H (1999) Review: dendritic cell immunotherapy for melanoma. Cancer Biother Radiopharm 14:11-22 (Pubitemid 29157729)
27. Schneeberger A, Goos M, Stingl G, Wagner SN (2000) Management of malignant melanoma: new developments in immune and gene therapy. Clin Exp Dermatol 25:509-519
28. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J (2001) Induction of polyclonal prostate cancer-speciWc CTL using dendritic cells transfected with ampliWed tumor RNA. J Immunol 166:2953-2960 (Pubitemid 33117290)
29. Bird RC, DeInnocentes P (2004) Characterization of the CDP-like/CTAS-1 binding site in the okadaic acid response element (OARE) of the human CDK1(p34cdc2) promoter. Anticancer Res 24:1469-1480 (Pubitemid 38954666)
30. Wernette CM, Smith BF, Barksdale ZL, Baker HJ (2002) CpG oligonucleotidesstimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol 84:223-236 (Pubitemid 34037118)
31. Salgaller ML (2000) Dendritic cells: strategies and vaccines. Meeting report: American Association of Cancer Research. Exp Opin Investig Drugs 9:1407-1412
32. Beatson RE, Taylor-Papadimitriou J, Burchell JM (2010) MUC1 immunotherapy. Immunotherapy 2:305-327
33. de Oliveira JT, Pinho SS, de Matos AJ, Hespanhol V, Reis CA, Gärtner F (2009) MUC1 Expression in canine malignant mammary tumours and relationship to clinicopathological features. Vet J 182:491-493
34. Day MJ (2007) Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet Parasitol 147:2-8
35. Carvalho LH, Sano G, Hafalla JC, Morrot A, Curotto de Lafaille MA, Zavala F (2002) IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat Med 8:166-170 (Pubitemid 34155128)
36. Boag PR, Parsons JC, Presidente PJ, Spithill TW, Sexton JL (2003) Characterisation of humoral immune responses in dogs vaccinated with irradiated Ancylostoma caninum. Vet Immunol Immunopathol 92:87-94 (Pubitemid 36298685)
37. Fujiwara RT, Loukas A, Mendez S, Williamson AL, Bueno LL, Wang Y, Samuel A, Zhan B, Bottazzi ME, Hotez PJ, Bethony JM (2006) Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs. Vaccine 24:501-509
38. Breathnach RM, Fanning S, Mulcahy G, Bassett HF, Jones BR, Daly P (2006) Evaluation of Th1-like, Th2-like and immunomodulatory cytokine mRNA expression in the skin of dogs with immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis. Vet Dermatol 17:313-321
39. Horiuchi Y, Hanazawa A, Nakajima Y, Nariai Y, Asanuma H, Kuwabara M, Yukawa M, Ito H (2007) T-helper (Th)1/Th2 imbalance in the peripheral blood of dogs with malignant tumor. Microbiol Immunol 51:1135-1138 (Pubitemid 350145863)